Relacatib

DB06367InvestigationalSmall molecule

Investigated for use/treatment in osteoporosis and bone metastases.

Mechanism: Relacatib is a small-molecule drug that inhibits the activity of cathepsin K, an enzyme that appears to be implicated in osteoporosis, osteoarthritis and certain other disorders causing bone degradation.
Curator reviewed
Primary indication: Investigated for use/treatment in osteoporosis and bone metastases.Curator reviewed
Formula / weight: C₂₇H₃₂N₄O₆S · 540.64 g/mol (avg)
Code names: SB-462795

Resolves to

Compound

Structure

InChIKeyBWYBBMQLUKXECQ-GIVPXCGWSA-NSMILESCC(C)C[C@H](NC(=O)C1=CC2=CC=CC=C2O1)C(=O)N[C@H]1CC[C@@H](C)N(CC1=O)S(=O)(=O)C1=CC=CC=N1

Targets

What you can answer from here — as of August 26, 2024

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Relacatib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.